Pragmatic Clinical Trials in Osteoporosis
- 17 Downloads
Purpose of Review
In this review, we present the application of pragmatic clinical trials for evaluating interventions in osteoporosis, and we discuss methodological considerations for designing and conducting a pragmatic clinical trial compared with a classical randomized clinical trial.
Pragmatic clinical trials are a popular study design testing effectiveness of health interventions and are intended to address the limitations associated with traditional explanatory randomized clinical trials testing efficacy of interventions. To date, only few pragmatic clinical trials have been conducted in osteoporosis.
Pragmatic clinical trials are conducted under routine clinical practice setting and are intended to inform policy makers and clinical decisions. Osteoporosis is a chronic disease well-suited to this particular study design given the existence of a clear and specific natural endpoint, namely fracture occurrence, and the availability of several treatments to prevent fractures.
KeywordsOsteoporosis Pragmatic clinical trials Effectiveness Randomized clinical trials
Compliance with Ethical Standards
Conflict of Interest
Giovanni Adami, Kenneth G. Saag, and Maria I. Danila declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.•• Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. https://doi.org/10.1136/bmj.h2147This manuscript provides the definition of the PRECIS-2 tool. The PRECIS-2 tool is intended to help trialists design their clinical trials. CrossRefPubMedGoogle Scholar
- 6.Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. https://doi.org/10.1186/s13063-015-1023-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437–43. https://doi.org/10.1056/NEJM199511303332201.CrossRefPubMedGoogle Scholar
- 9.Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230–40. https://doi.org/10.1016/S0140-6736(17)32137-2.CrossRefPubMedGoogle Scholar
- 13.• Warriner AH, Foster PJ, Mudano A, Wright NC, Melton ME, Sattui SE, et al. A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study. Contemp Clin Trials Commun. 2016;3:32–8. https://doi.org/10.1016/j.conctc.2016.02.003This manuscript presents the results of a PCT comparing eConsent and paper-based consent in osteoporosis. CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Yen P-Y, Sousa KH, Bakken S. Examining construct and predictive validity of the Health-IT Usability Evaluation Scale: confirmatory factor analysis and structural equation modeling results. J Am Med Inform Assoc. 2014;21:e241–8. https://doi.org/10.1136/amiajnl-2013-001811.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.•• Department of Health and Human Services (HHS). Federal policy for the protection of human subjects (final rule). 82 Federal Register 7149, January 19, 2017., (2017).The "Common Rule" governs the ethical conduct of research. Google Scholar
- 20.Fahed R, Finitsis S, Khoury N, Deschaintre Y, Daneault N, Gioia L, et al. A randomized pragmatic care trial on endovascular acute stroke interventions (EASI): criticisms, responses, and ethics of integrating research and clinical care. Trials. 2018;19:508. https://doi.org/10.1186/s13063-018-2870-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Cram P, Wolinsky FD, Lou Y, Edmonds SW, Hall SF, Roblin DW, et al. Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int. 2016;27:3513–24. https://doi.org/10.1007/s00198-016-3681-9.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.• Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19:370–8. https://doi.org/10.1359/JBMR.0301240This manuscript presents a PCT that tested the efficacy of vitamin D and calcium in more than 9000 community-dwelling residents aged more than 66 years. CrossRefPubMedGoogle Scholar
- 28.Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. National Osteoporosis Guideline Group (NOGG), UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12:43. https://doi.org/10.1007/s11657-017-0324-5.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6:445–54. https://doi.org/10.1016/S2213-8587(18)30075-5.CrossRefPubMedGoogle Scholar
- 32.Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309–18. https://doi.org/10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K.CrossRefPubMedGoogle Scholar
- 33.•• Colman EG. The Food and Drug Administration’s osteoporosis guidance document: past, present, and future. J Bone Miner Res. 2003;18:1125–8. https://doi.org/10.1359/jbmr.2003.18.6.1125The Food and Drug Administration guidance for the design of clinical trials in osteoporosis.CrossRefPubMedGoogle Scholar